Barbara Pro

Barbara Pro was a principal investigator for the ECHELON-2 trial that established brentuximab vedotin combined with CHP (cyclophosphamide, doxorubicin, prednisone) as a new standard of care for frontline CD30-positive peripheral T-cell lymphomas. Her seminal contributions to PTCL include defining CD30 expression patterns across T-cell lymphoma subtypes and optimal frontline treatment. She is a leader in international cooperative group lymphoma trials.